After The Bell
FONT-SIZE Plus   Neg

Jazz Pharmaceuticals (JAZZ) Is Climbing On Q4 Results

Trade JAZZ now with 

Jazz Pharmaceuticals (JAZZ: Quote) reported fourth quarter adjusted net income of $1.17 per share after the close Monday, compared to $0.63 per share in the previous year. The consensus estimate was for EPS of $1.09. The stock is now up 0.97 on 20K shares.

Jazz Pharmaceuticals traded in a range throughout Monday's session and closed down by 0.26 at $50.55. The stock pulled back from the upper end of over a month and a half long range, at the highs of the year.

Click here to receive FREE breaking news email alerts for Jazz Pharmaceuticals plc and others in your portfolio

by RTT Staff Writer

For comments and feedback:

Business News

comments powered by Disqus